Patents by Inventor Stephen M. Condon

Stephen M. Condon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HEPATITIS B CAPSID ASSEMBLY MODULATORS
    Publication number: 20210171439
    Abstract: Described herein are hepatitis B capsid assembly modulators and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of hepatitis B.
    Type: Application
    Filed: December 10, 2018
    Publication date: June 10, 2021
    Applicant: VenatoRx Pharmaceuticals, Inc.
    Inventors: Christopher J. BURNS, Glen COBURN, Bin LIU, Jiangchao YAO, Christopher BENETATOS, Steven A. Boyd, Stephen M. CONDON
  • Hepatitis B capsid assembly modulators
    Patent number: 11014881
    Abstract: Described herein are hepatitis B capsid assembly modulators and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of hepatitis B.
    Type: Grant
    Filed: November 1, 2019
    Date of Patent: May 25, 2021
    Assignee: VENATORX PHARMACEUTICALS, INC.
    Inventors: Christopher J. Burns, Glen Coburn, Bin Liu, Jiangchao Yao, Christopher Benetatos, Steven A. Boyd, Stephen M. Condon, Thomas Haimowitz
  • SMAC Mimetic
    Publication number: 20200282002
    Abstract: A SMAC mimetic and pharmaceutical compositions thereof and methods of use.
    Type: Application
    Filed: February 6, 2020
    Publication date: September 10, 2020
    Inventors: Stephen M. Condon, Yijun Deng, Matthew G. Laporte, Susan R. Rippin
  • PENICILLIN-BINDING PROTEIN INHIBITORS
    Publication number: 20200157123
    Abstract: Described herein are certain boron-containing compounds, compositions, preparations and their use as modulators of the transpeptidase function of bacterial penicillin-binding proteins and as antibacterial agents. In some embodiments, the compounds described herein inhibit penicillin-binding proteins. In certain embodiments, the compounds described herein are useful in the treatment of bacterial infections.
    Type: Application
    Filed: May 25, 2018
    Publication date: May 21, 2020
    Inventors: Christopher J. BURNS, Denis DAIGLE, Guo-Hua CHU, Jodie HAMRICK, Matthew LUCAS, Steven A. Boyd, Allison L. ZULLI, Eugen F. MESAROS, Stephen M. CONDON, Robert E. Lee TROUT, Cullen L. MYERS
  • HEPATITIS B CAPSID ASSEMBLY MODULATORS
    Publication number: 20200123105
    Abstract: Described herein are hepatitis B capsid assembly modulators and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of hepatitis B.
    Type: Application
    Filed: November 1, 2019
    Publication date: April 23, 2020
    Inventors: Christopher J. BURNS, Glen COBURN, Bin LIU, Jiangchao YAO, Christopher BENETATOS, Steven A. BOYD, Stephen M. CONDON, Thomas HAIMOWITZ
  • SMAC mimetic
    Patent number: 10596220
    Abstract: A SMAC mimetic and pharmaceutical compositions thereof and methods of use.
    Type: Grant
    Filed: April 29, 2019
    Date of Patent: March 24, 2020
    Assignee: Medivir AB
    Inventors: Stephen M. Condon, Yijun Deng, Matthew G. Laporte, Susan R. Rippin
  • Hepatitis B capsid assembly modulators
    Patent number: 10590076
    Abstract: Described herein are hepatitis B capsid assembly modulators and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of hepatitis B.
    Type: Grant
    Filed: June 11, 2019
    Date of Patent: March 17, 2020
    Assignee: VENATORX PHARMACEUTICALS, INC.
    Inventors: Christopher J. Burns, Glen Coburn, Bin Liu, Jiangchao Yao, Christopher Benetatos, Steven A. Boyd, Stephen M. Condon, Thomas Haimowitz
  • HEPATITIS B CAPSID ASSEMBLY MODULATORS
    Publication number: 20190375708
    Abstract: Described herein are hepatitis B capsid assembly modulators and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of hepatitis B.
    Type: Application
    Filed: June 11, 2019
    Publication date: December 12, 2019
    Inventors: Christopher J. BURNS, Glen COBURN, Bin LIU, Jiangchao YAO, Christopher BENETATOS, Steven A. BOYD, Stephen M. CONDON, Thomas HAIMOWITZ
  • SMAC Mimetic
    Publication number: 20190255139
    Abstract: A SMAC mimetic and pharmaceutical compositions thereof and methods of use.
    Type: Application
    Filed: April 29, 2019
    Publication date: August 22, 2019
    Inventors: Stephen M. Condon, Yijun Deng, Matthew G. Laporte, Susan R. Rippin
  • SMAC mimetic
    Patent number: 10314881
    Abstract: A SMAC mimetic and pharmaceutical compositions thereof and methods of use.
    Type: Grant
    Filed: June 27, 2018
    Date of Patent: June 11, 2019
    Assignee: Medivir AB
    Inventors: Stephen M. Condon, Yijun Deng, Matthew G. Laporte, Susan R. Rippin
  • SMAC Mimetic
    Publication number: 20180303897
    Abstract: A SMAC mimetic and pharmaceutical compositions thereof and methods of use.
    Type: Application
    Filed: June 27, 2018
    Publication date: October 25, 2018
    Inventors: Stephen M. Condon, Yijun Deng, Matthew G. Laporte, Susan R. Rippin
  • SMAC Mimetic
    Patent number: 10034912
    Abstract: A SMAC mimetic and pharmaceutical compositions thereof and methods of use.
    Type: Grant
    Filed: November 7, 2016
    Date of Patent: July 31, 2018
    Assignee: TetraLogic Birinapant UK Ltd.
    Inventors: Stephen M. Condon, Yijun Deng, Matthew G. Laporte, Susan R. Rippin
  • Dimeric IAP inhibitors
    Patent number: 9920093
    Abstract: Molecular mimics of Smac are capable of modulating apoptosis through their interaction with cellular IAPs (inhibitor of apoptosis proteins). The mimetics are based on a monomer or dimer of the N-terminal tetrapeptide of IAP-binding proteins, such as Smac/DIABLO, Hid, Grim and Reaper, which interact with a specific surface groove of IAP. Also disclosed are methods of using these peptidomimetics for therapeutic purposes. In various embodiments of the invention the Smac mimetics of the invention are combined with chemotherapeutic agents, including, but not limited to topoisomerase inhibitors, kinase inhibitors, NSAIDs, taxanes and platinum containing compounds use broader language.
    Type: Grant
    Filed: August 17, 2016
    Date of Patent: March 20, 2018
    Assignee: TetraLogic Birinapant UK Ltd.
    Inventors: Stephen M. Condon, Matthew G. Laporte, Yijun Deng, Susan R. Rippin
  • IAP binding compounds
    Patent number: 9840464
    Abstract: IAP binding molecules and compositions including these are disclosed. The IAP binding molecules interact with IAPs (inhibitor of apoptosis proteins) in cells and may be used to modify apoptosis in cells treated with such molecules. Embodiments of these compounds have a Kd of less than 0.1 micromolar. Methods of using these IAP binding molecules for therapeutic, diagnostic, and assay purposed are also disclosed.
    Type: Grant
    Filed: June 15, 2016
    Date of Patent: December 12, 2017
    Assignee: TetraLogic Birinapant UK Ltd.
    Inventors: Stephen M. Condon, Matthew G. Laporte, Yijun Deng, Susan R. Rippin
  • SMAC Mimetic
    Publication number: 20170182116
    Abstract: A SMAC mimetic and pharmaceutical compositions thereof and methods of use.
    Type: Application
    Filed: November 7, 2016
    Publication date: June 29, 2017
    Inventors: Stephen M. Condon, Yijun Deng, Matthew G. Laporte, Susan R. Rippin
  • Dimeric IAP Inhibitors
    Publication number: 20160355547
    Abstract: Molecular mimics of Smac are capable of modulating apoptosis through their interaction with cellular IAPs (inhibitor of apoptosis proteins). The mimetics are based on a monomer or dimer of the N-terminal tetrapeptide of IAP-binding proteins, such as Smac/DIABLO, Hid, Grim and Reaper, which interact with a specific surface groove of IAP. Also disclosed are methods of using these peptidomimetics for therapeutic purposes.
    Type: Application
    Filed: August 17, 2016
    Publication date: December 8, 2016
    Inventors: Stephen M. Condon, Matthew G. Laporte, Yijun Deng, Susan R. Rippin
  • IAP Binding Compounds
    Publication number: 20160289183
    Abstract: IAP binding molecules and compositions including these are disclosed. The IAP binding molecules interact with IAPs (inhibitor of apoptosis proteins) in cells and may be used to modify apoptosis in cells treated with such molecules. Embodiments of these compounds have a Kd of less than 0.1 micromolar. Methods of using these IAP binding molecules for therapeutic, diagnostic, and assay purposed are also disclosed.
    Type: Application
    Filed: June 15, 2016
    Publication date: October 6, 2016
    Inventors: Stephen M. Condon, Matthew G. Laporte, Yijun Deng, Susan R. Rippin
  • IAP binding compounds
    Patent number: 9394249
    Abstract: IAP binding molecules and compositions including these are disclosed. The IAP binding molecules interact with IAPs (inhibitor of apoptosis proteins) in cells and may be used to modify apoptosis in cells treated with such molecules. Embodiments of these compounds have a Kd of less than 0.1 micromolar. Methods of using these IAP binding molecules for therapeutic, diagnostic, and assay purposed are also disclosed.
    Type: Grant
    Filed: July 16, 2014
    Date of Patent: July 19, 2016
    Assignee: TetraLogic Birinapant UK Ltd.
    Inventors: Stephen M. Condon, Matthew G. Laporte, Yijun Deng, Susan R. Rippin
  • Dimeric IAP Inhibitors
    Publication number: 20160052965
    Abstract: Molecular mimics of Smac are capable of modulating apoptosis through their interaction with cellular IAPs (inhibitor of apoptosis proteins). The mimetics are based on a monomer or dimer of the N-terminal tetrapeptide of IAP-binding proteins, such as Smac/DIABLO, Hid, Grim and Reaper, which interact with a specific surface groove of IAP. Also disclosed are methods of using these peptidomimetics for therapeutic purposes.
    Type: Application
    Filed: October 15, 2015
    Publication date: February 25, 2016
    Applicant: TETRALOGIC BIRINAPANT UK LTD.
    Inventors: Stephen M. Condon, Matthew G. Laporte, Yijun Deng, Susan R. Rippin
  • Dimeric IAP inhibitors
    Patent number: 9187490
    Abstract: Molecular mimics of Smac are capable of modulating apoptosis through their interaction with cellular IAPs (inhibitor of apoptosis proteins). The mimetics are based on a monomer or dimer of the N-terminal tetrapeptide of IAP-binding proteins, such as Smac/DIABLO, Hid, Grim and Reaper, which interact with a specific surface groove of IAP. Also disclosed are methods of using these peptidomimetics for therapeutic purposes. In various embodiments of the invention the Smac mimetics of the invention are combined with chemotherapeutic agents, including, but not limited to topoisomerase inhibitors, kinase inhibitors, NSAIDs, taxanes and platinum containing compounds use broader language.
    Type: Grant
    Filed: July 21, 2014
    Date of Patent: November 17, 2015
    Assignee: TetraLogic Birinapant UK Ltd.
    Inventors: Stephen M. Condon, Matthew G. Laporte, Yijun Deng, Susan R. Rippin